Goyal Salt expands product portfolio with launch of black salt
Studies Showed Hospitals Effectively Reduced Both the Incidence of and Evaluations for Late-Onset Sepsis When Prolacta’s Fortifiers Were Used in Lieu of Cow Milk-Based Fortifiers
Implementing Prolacta Bioscience’s products as part of an exclusive human milk diet (EHMD) reduced the incidence of and evaluations for late-onset sepsis among premature infants, according to clinical studies that compared Prolacta’s 100% human milk-based fortifiers to cow milk-based fortifiers.
Premature infants can face many life-threatening complications. Among the most prominent of these risks are late-onset sepsis, a dangerous systemic response to infection and a leading cause of mortality in neonatal intensive care units (NICUs). It is estimated that premature infants have up to a 26% chance of developing this serious complication. In addition to predisposing infants to other morbidities, and subsequent neurodevelopmental disabilities, sepsis significantly increases NICU costs.
Minimizing the incidence of sepsis may include limiting premature infants’ exposure to interventions that have been shown to increase sepsis risk, such as central venous lines, extended parenteral feeding, and using cow milk-based fortifiers. Clinical evidence demonstrates that one way hospitals achieved this is with Prolacta’s 100% human milk-based fortifiers.
Prolacta leads the industry with the highest quality and safety standards for the screening and testing of donor milk. It is a global company with headquarters in Duarte, California in the US.